p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial

Jeff Sperinde; Huang Weidong; W Huang; Aki Vehtari; Chenna Ahmed; A Chenna; Pirkko-Liisa Kellokumpu-Lehtinen; John Winslow; Petri Bono; Yolanda Lie; Christos J Petropoulos; Jodi M Weidler; Heikki Joensuu

doi:10.1158/1078-0432.ccr-17-3250

p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial

Jeff Sperinde, Huang Weidong, W Huang, Aki Vehtari, Chenna Ahmed, A Chenna, Pirkko-Liisa Kellokumpu-Lehtinen, John Winslow, Petri Bono, Yolanda Lie, Christos J Petropoulos, Jodi M Weidler, Heikki Joensuu

Department of Oncology

Research output: Contribution to journal › Article › Scientific › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	3046-3052
Journal	Clinical Cancer Research
Volume	24
Issue number	13
DOIs	https://doi.org/10.1158/1078-0432.ccr-17-3250
Publication status	Published - 2018
Publication type	A1 Journal article-refereed

Publication forum classification

Publication forum level 2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.ccr-17-3250

http://urn.fi/urn:nbn:fi:uta-201810152694

Cite this

Sperinde, J., Weidong, H., Huang, W., Vehtari, A., Ahmed, C., Chenna, A., Kellokumpu-Lehtinen, P-L., Winslow, J., Bono, P., Lie, Y., Petropoulos, C. J., Weidler, J. M., & Joensuu, H. (2018). p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial. Clinical Cancer Research, 24(13), 3046-3052. https://doi.org/10.1158/1078-0432.ccr-17-3250

@article{30b2c75203cc436c8bf2568280d0ee31,

title = "p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial",

author = "Jeff Sperinde and Huang Weidong and W Huang and Aki Vehtari and Chenna Ahmed and A Chenna and Pirkko-Liisa Kellokumpu-Lehtinen and John Winslow and Petri Bono and Yolanda Lie and Petropoulos, {Christos J} and Weidler, {Jodi M} and Heikki Joensuu",

year = "2018",

doi = "10.1158/1078-0432.ccr-17-3250",

language = "English",

volume = "24",

pages = "3046--3052",

number = "13",

}

Sperinde, J, Weidong, H, Huang, W, Vehtari, A, Ahmed, C, Chenna, A, Kellokumpu-Lehtinen, P-L, Winslow, J, Bono, P, Lie, Y, Petropoulos, CJ, Weidler, JM & Joensuu, H 2018, 'p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial', Clinical Cancer Research, vol. 24, no. 13, pp. 3046-3052. https://doi.org/10.1158/1078-0432.ccr-17-3250

TY - JOUR

T1 - p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial

AU - Sperinde, Jeff

AU - Weidong, Huang

AU - Huang, W

AU - Vehtari, Aki

AU - Ahmed, Chenna

AU - Chenna, A

AU - Kellokumpu-Lehtinen, Pirkko-Liisa

AU - Winslow, John

AU - Bono, Petri

AU - Lie, Yolanda

AU - Petropoulos, Christos J

AU - Weidler, Jodi M

AU - Joensuu, Heikki

PY - 2018

Y1 - 2018

U2 - 10.1158/1078-0432.ccr-17-3250

DO - 10.1158/1078-0432.ccr-17-3250

M3 - Article

SN - 1078-0432

VL - 24

SP - 3046

EP - 3052

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 13

ER -